(MedPage Today) — Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among patients with early triple-negative breast cancer (TNBC), but a 12-week non-anthracycline regimen in…
Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/114604
Author :
Publish date : 2025-03-11 20:39:00
Copyright for syndicated content belongs to the linked Source.
